ALEC - Alector, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.38
+1.49 (+7.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.89
Open20.06
Bid17.35 x 1400
Ask21.37 x 800
Day's Range19.86 - 21.80
52 Week Range13.64 - 27.00
Volume566,139
Avg. Volume360,417
Market Cap1.474B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon.

  • GlobeNewswire

    Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

    AL101 is the company’s second product candidate designed to increase the level of progranulin in the human brain. Progranulin has been identified as a key regulator of microglial function in the brain with strong genetic links to multiple neurodegenerative disorders. SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in December 2019, it initiated dosing in healthy volunteers in its Phase 1 study of AL101, an investigational product candidate designed to increase progranulin levels.

  • GlobeNewswire

    Alector Added to the NASDAQ Biotechnology Index

    SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been.

  • GlobeNewswire

    Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and Review Committee (SPARC). As co-chairs of SPARC, Drs. Scheller and Südhof will serve as key R&D leaders supporting the advancement of Alector’s research pipeline and proprietary drug discovery platform.

  • GlobeNewswire

    Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will provide updates related to its lead product candidates during a previously announced R&D day being held today at 8:00 a.m. ET in New York, NY. During today’s session, Alector will outline key activities underway for AL001, AL002, AL003, AL101, and AL014, and will feature presentations from leading key opinion leaders focused on the human genetics of neurodegeneration.

  • GlobeNewswire

    Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer

    Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as the company’s president and chief operating officer. In this new role, Dr. Suliman will oversee Alector’s day-to-day operations, including preclinical development, program management, and strategic and administrative functions. Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.

  • GlobeNewswire

    Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported safety and biomarker data from the single ascending dose (SAD) phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) meeting being held December 4-6 in San Diego, California.

  • GlobeNewswire

    Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic, AL001, for the treatment of patients with frontotemporal dementia (FTD) carrying specific genetic mutations in the granulin gene (FTD-GRN). AL001 is the company’s product candidate currently being evaluated in a Phase 2 trial for the treatment of FTD-GRN and FTD-C9orf72.

  • GlobeNewswire

    Alector to Host R&D Day on December 13, 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will.

  • GlobeNewswire

    Alector to Present at the Jefferies 2019 London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney,.

  • GlobeNewswire

    Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results

    Initiated AL001 Phase 2 clinical study and dosed multiple frontotemporal dementia patients with a progranulin mutation (FTD-GRN) or a C9orf72 mutation (FTD-C9orf72)Initiated.

  • GlobeNewswire

    Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the treatment of people with frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN). “We are encouraged by the recent data from our Phase 1b trial of AL001, in which AL001 was well-tolerated and restored progranulin back to normal physiological levels in the central nervous system of FTD-GRN patients,” said Robert Paul, M.D, Ph.D., chief medical officer of Alector.

  • GlobeNewswire

    Alector to Present at 17th Annual Morgan Stanley Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Arnon.

  • GlobeNewswire

    Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results

    - Completed planned enrollment of AL001 Phase 1b trial and demonstrated proof-of-mechanism in Frontotemporal Dementia patients - AL101 granted Orphan Drug Designation from.

  • GlobeNewswire

    Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors

    Alector, Inc. (ALEC) today announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors. Dr. Yaffe is the Scola Endowed Chair and Vice Chair, professor of psychiatry, neurology and epidemiology and the director of the Center for Population Brain Health at the University of California, San Francisco (UCSF). “Kristine is an internationally recognized expert in the field of cognitive aging, neurodegeneration and dementia,” said Arnon Rosenthal, Ph.D., chief executive officer of Alector.

  • GlobeNewswire

    Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).

  • GlobeNewswire

    Alector Announces Upcoming Presentations at 2019 Alzheimer's Association International Conference

    SOUTH SAN FRANCISCO, Calif., July 11, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for.

  • GlobeNewswire

    Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results

    In April 2019, Alector dosed the first frontotemporal dementia patient in the Phase 1b portion of the INFRONT clinical study of AL001. In addition to safety, the study will also measure the levels of a critical target specific biomarker, progranulin, in plasma and in cerebrospinal fluid (CSF) to demonstrate proof of mechanism in patients.

  • GlobeNewswire

    Alector to Present at the Bank of America Merrill Lynch Healthcare Conference on May 15, 2019

    SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for.

  • GlobeNewswire

    Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002

    Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INVOKE clinical study of AL002. AL002 is a monoclonal antibody that enhances the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie.

  • GlobeNewswire

    Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001

    Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the Phase 1b portion of the INFRONT clinical study of AL001 after successful completion of the healthy volunteer single ascending dose escalation portion of the study. “AL001 was generally well tolerated, with no drug-related serious adverse events in healthy volunteers, achieving the study’s primary objective.

  • GlobeNewswire

    Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease

    Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of the first-in-human Phase 1 trial for AL003, called the INTERCEPT study. AL003 is the company’s second product candidate being developed for the treatment of patients with Alzheimer’s disease in collaboration with its partner AbbVie. Alector is focused on identifying and functionally repairing genetic mutations that cause dysfunction of the brain immune system leading to neurodegeneration.

  • GlobeNewswire

    Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results

    - Strong 2018 marked by the company’s first and second programs entering the clinic, targeting frontotemporal dementia and Alzheimer’s disease. Ten programs in Research and.

  • GlobeNewswire

    Alector to Present at Investor Conferences in March

    SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach.

  • GlobeNewswire

    Nasdaq Welcomes Alector, Inc. (Nasdaq: ALEC) to the Nasdaq Stock Market

    Alector, Inc. (ALEC), a clinical stage biotechnology company, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Alector is pioneering immuno-neurology, a novel therapeutic approach to counteract the multiple pathologies that cause degenerative brain disorders by restoring healthy immune function to the brain. Supporting its scientific approach, the Company’s Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success of these product candidates and shorten the development timelines to bring these therapies to patients.